Search Results - "YEDILBAYEV, Askar"

PASS to End TB in Europe: Accelerated efforts on prevention and systematic screening to end tuberculosis in the WHO European Region by 2030 by Dadu, Andrei, Yedilbayev, Askar, Migliori, Giovanni Battista, Ahmedov, Sevim, Falzon, Dennis, den Boon, Saskia, Kanchar, Avinash, Matteelli, Alberto

“…•The WHO European Region is a hotspot for MDR/RR-TB.•New ambitious global targets for 2023-2027 have been launched by the UNHTLM.•Systematic screening is key…”
Get full text

Operational research as an instrument to address the critical gaps for effective treatment of tuberculosis in eastern Europe and central Asia by Korotych, Oleksandr, Dadu, Andrei, Yedilbayev, Askar, Dara, Masoud

Get full text

Tuberculosis Co-Infection Is Common in Patients Requiring Hospitalization for COVID-19 in Belarus: Mixed-Methods Study by Sereda, Yuliia, Korotych, Oleksandr, Klimuk, Dzmitry, Zhurkin, Dzmitry, Solodovnikova, Varvara, Grzemska, Malgorzata, Grankov, Viatcheslav, Hurevich, Hennadz, Yedilbayev, Askar, Skrahina, Alena

“…A significant drop in tuberculosis (TB) case-finding has been widely reported during the period of the COVID-19 pandemic. To address a decrease in TB…”
Get full text

Culture conversion at six months in patients receiving bedaquiline- and delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis by Maretbayeva, Shynar M., Rakisheva, Anar S., Adenov, Malik M., Yeraliyeva, Lyazzat T., Algozhin, Yerkebulan Zh, Stambekova, Assel T., Berikova, Elmira A., Yedilbayev, Askar, Rich, Michael L., Seung, Kwonjune J., Issayeva, Assiya M.

“…•Globally and in Kazakhstan, the uptake of bedaquiline and delamanid has been slow.•Bedaquiline and delamanid represent new classes anti-TB drugs.•Bedaquiline…”
Get full text

Corrigendum to ‘Culture conversion at six months in patients receiving bedaquiline- and delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis’ International Journal of Infectious Diseases Volume 113S1 (2021) S91-S95 by Maretbayeva, Shynar M., Rakisheva, Anar S., Adenov, Malik M., Yeraliyeva, Lyazzat T., Algozhin, Yerkebulan Zh, Stambekova, Assel T., Berikova, Elmira A., Yedilbayev, Askar, Rich, Michael L., Seung, Kwonjune J., Issayeva, Assiya M.

Get full text

Effectiveness and safety of delamanid- or bedaquiline-containing regimens among children and adolescents with multidrug resistant or extensively drug resistant tuberculosis: A nationwide study from Belarus, 2015-19 by Solodovnikova, Varvara, Kumar, Ajay M V, Hurevich, Hennadz, Sereda, Yuliia, Auchynka, Vera, Katovich, Dzmitry, Klimuk, Dzmitry, Skrahin, Aliaksandr, Setkina, Svetlana, Charnysh, Iryna, Yedilbayev, Askar, Skrahina, Alena

“…There is limited evidence describing the safety and effectiveness of bedaquiline and delamanid containing regimens in children and adolescents with…”
Get full text

Aggressive Regimens Reduce Risk of Recurrence After Successful Treatment of MDR-TB by Khan, Faiz Ahmad, Gelmanova, Irina Y., Franke, Molly F., Atwood, Sidney, Zemlyanaya, Nataliya A., Unakova, Irina A., Andreev, Yevgeniy G., Berezina, Valentina I., Pavlova, Vera E., Shin, Sonya S., Yedilbayev, Askar B., Becerra, Mercedes C., Keshavjee, Salmaan

“…Background. We sought to determine whether treatment with a "long aggressive regimen" was associated with lower rates of relapse among patients successfully…”
Get full text

Factors associated with culture conversion among adults treated for pulmonary extensively drug-resistant tuberculosis during 2018-2019 in the Russian Federation: an observational cohort study by Russkikh, Anastasiia, Korotych, Oleksandr, Sereda, Yuliia, Samoilova, Anastasia, Achar, Jay, Yedilbayev, Askar, Dara, Masoud, Vasilyeva, Irina

“…Treatment outcomes for Multidrug/Rifampicin-Resistant Tuberculosis (MDR/RR-TB) and Extensively Drug-Resistant Tuberculosis (XDR-TB) remain poor across the…”
Get full text

Effectiveness and cardiovascular safety of delamanid-containing regimens in adults with multidrug-resistant or extensively drug-resistant tuberculosis: A nationwide cohort study from Belarus, 2016-18 by Auchynka, Vera, Kumar, Ajay M V, Hurevich, Hennadz, Sereda, Yuliia, Solodovnikova, Varvara, Katovich, Dzmitry, Setkina, Svetlana, Yedilbayev, Askar, Skrahin, Aliaksandr, Skrahina, Alena

“…To address the sub-optimal treatment outcomes among patients with multidrug-resistant (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB), the…”
Get full text

Screening for tuberculosis among migrants in Europe: harmonising approaches during a humanitarian crisis? by den Boon, Saskia, Yedilbayev, Askar

Get more information

Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe by Migliori, Giovanni Battista, Nardell, Edward, Yedilbayev, Askar, D'Ambrosio, Lia, Centis, Rosella, Tadolini, Marina, van den Boom, Martin, Ehsani, Soudeh, Sotgiu, Giovanni, Dara, Masoud

“…Evidence-based guidance is needed on 1) how tuberculosis (TB) infectiousness evolves in response to effective treatment and 2) how the TB infection risk can be…”
Get full text

Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally by Masini, Tiziana, Kanchar, Avinash, Mirzayev, Fuad, Viney, Kerri, Yedilbayev, Askar, Zignol, Matteo, Falzon, Dennis

“…In their correspondence, G uglielmetti et al. [1] emphasise the importance of improved access to rifapentine globally, both for the treatment of tuberculosis…”
Get full text

Availability of drugs for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis in the World Health Organization European Region, October 2023 by Otto-Knapp, Ralf, Edwards, Suzanne, Kuchukhidze, Giorgi, Kröger, Stefan, Häcker, Brit, Bivol, Stela, Yedilbayev, Askar

“…The BPaLM regimen (bedaquiline, pretomanid, linezolid and moxifloxacin) recently recommended by the World Health Organization offers short, safe, and effective…”
Get full text

What is behind programmatic treatment outcome definitions for tuberculosis? by Avaliani, Zaza, Gozalov, Ogtay, Kuchukhidze, Giorgi, Skrahina, Alena, Soltan, Viorel, van den Boom, Martin, Vasilyeva, Irina, Vilc, Valentina, Yedilbayev, Askar

Get full text

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report by Borisov, Sergey, Danila, Edvardas, Maryandyshev, Andrei, Dalcolmo, Margareth, Miliauskas, Skaidrius, Kuksa, Liga, Manga, Selene, Skrahina, Alena, Diktanas, Saulius, Codecasa, Luigi Ruffo, Aleksa, Alena, Bruchfeld, Judith, Koleva, Antoniya, Piubello, Alberto, Udwadia, Zarir Farokh, Akkerman, Onno W, Belilovski, Evgeny, Bernal, Enrique, Boeree, Martin J, Cadiñanos Loidi, Julen, Cai, Qingshan, Cebrian Gallardo, Jose Joaquín, Dara, Masoud, Davidavičienė, Edita, Forsman, Lina Davies, De Los Rios, Jorge, Denholm, Justin, Drakšienė, Jacinta, Duarte, Raquel, Elamin, Seifeldin Eltaeb, Escobar Salinas, Nadia, Ferrarese, Maurizio, Filippov, Alexey, Garcia, Ana, García-García, José-María, Gaudiesiute, Ieva, Gavazova, Blagovesta, Gayoso, Regina, Gomez Rosso, Roscio, Gruslys, Vygantas, Gualano, Gina, Hoefsloot, Wouter, Jonsson, Jerker, Khimova, Elena, Kunst, Heinke, Laniado-Laborín, Rafael, Li, Yang, Magis-Escurra, Cecile, Manfrin, Vinicio, Marchese, Valentina, Martínez Robles, Elena, Matteelli, Alberto, Mazza-Stalder, Jesica, Moschos, Charalampos, Muñoz-Torrico, Marcela, Mustafa Hamdan, Hamdan, Nakčerienė, Birutė, Nicod, Laurent, Nieto Marcos, Magnolia, Palmero, Domingo Juan, Palmieri, Fabrizio, Papavasileiou, Apostolos, Payen, Marie-Christine, Pontarelli, Agostina, Quirós, Sarai, Rendon, Adrian, Saderi, Laura, Šmite, Agnese, Solovic, Ivan, Souleymane, Mahamadou Bassirou, Tadolini, Marina, van den Boom, Martin, Vescovo, Marisa, Viggiani, Pietro, Yedilbayev, Askar, Zablockis, Rolandas, Zhurkin, Dmitry, Zignol, Matteo, Visca, Dina, Spanevello, Antonio, Caminero, José A, Alffenaar, Jan-Willem, Tiberi, Simon, Centis, Rosella, D'Ambrosio, Lia, Pontali, Emanuele, Sotgiu, Giovanni, Migliori, Giovanni Battista

“…The World Health Organization (WHO) recommends that countries implement pharmacovigilance and collect information on active drug safety monitoring (aDSM) and…”
Get full text

Early COVID-19 pandemic’s toll on tuberculosis services, WHO European Region, January to June 2020 by Dara, Masoud, Kuchukhidze, Giorgi, Yedilbayev, Askar, Perehinets, Ihor, Schmidt, Tanja, Van Grinsven, W. Leif, Boeree, Martin J.

“…Background Essential health services, including for tuberculosis (TB), are being affected by public health and social measures (PHSM) introduced to control…”
Get full text

Operational research to tackle TB in Eastern Europe and Central Asia: Moving forward during the COVID-19 pandemic by Yedilbayev, Askar, Davtyan, Hayk, Korotych, Oleksandr, Dadu, Andrei

Get full text

Safety and Effectiveness of 3 Novel All-Oral Shortened Regimens for Rifampicin- or Multidrug-Resistant Tuberculosis in Kazakhstan by Rashitov, Makhmujan, Franke, Molly F, Trevisi, Letizia, Bekbolatova, Gulzhanat, Shalimova, Julia, Eshmetov, Gafurzhan, Bektasov, Sagit, LaHood, Allison, Arlyapova, Nataliya, Osso, Elna, Yedilbayev, Askar, Korotych, Oleksandr, Ciobanu, Anisoara, Skrahina, Alena, Mitnick, Carole D, Seung, Kwonjune J, Algozhin, Yerkebulan, Rich, Michael L

“…In 2019, the World Health Organization called for operational research on all-oral shortened regimens for multidrug- and rifampicin-resistant tuberculosis…”
Get full text

Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis by Seung, Kwonjune J, Khan, Palwasha, Franke, Molly F, Ahmed, Saman, Aiylchiev, Stalbek, Alam, Manzur, Putri, Fauziah Asnely, Bastard, Mathieu, Docteur, Wisny, Gottlieb, Gary, Hewison, Catherine, Islam, Shirajul, Khachatryan, Naira, Kotrikadze, Tinatin, Khan, Uzma, Kumsa, Andargachew, Lecca, Leonid, Tassew, Yoseph Melaku, Melikyan, Nara, Naing, Ye Yint, Oyewusi, Lawrence, Rich, Michael, Wanjala, Stephen, Yedilbayev, Askar, Huerga, Helena, Mitnick, Carole D

“…Abstract Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand…”
Get full text

Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study by Korotych, Oleksandr, Achar, Jay, Gurbanova, Elmira, Hovhannesyan, Arax, Lomtadze, Nino, Ciobanu, Ana, Skrahina, Alena, Dravniece, Gunta, Kuksa, Liga, Rich, Michael, Khachatryan, Naira, Germanovych, Myroslava, Kadyrov, Abdullat, Terleieva, Iana, Akhundova, Irada, Adenov, Malik, Durdyeva, Myahri, Kiria, Nana, Parpieva, Nargiza, Yatskevich, Natalia, Jumayev, Rovshen, Nurov, Rustam, Diktanas, Saulius, Vilc, Valentina, Migliori, Giovanni Battista, Yedilbayev, Askar

“…In 2020, WHO guidelines prioritised the use of a standard fully oral short treatment regimen (STR) consisting of bedaquiline, levofloxacin or moxifloxacin,…”
Get full text